It is still in the experimental stage for treating ITP, however initial results are encouraging.
Clinical trials are in progress.
Rituxan reduces the number of B cells in your body. B cells are a type of white blood cell that, when activated, multiply and produce antibodies. Since Rituxan reduces the number of B cells it reduces the number of cells that produce antibodies including the antibodies that attack platelets. Antibody production is triggered by antigens. An antigen and antibody fit together like a key in a lock.